ESTRO 2024 - Abstract Book

S1711

Clinical - Lung

ESTRO 2024

3. Zhang Y, Lin D, Aramini B, et al. Thymoma and Thymic Carcinoma: Surgical Resection and Multidisciplinary Treatment. Cancers (Basel). 2023;15(7). doi:10.3390/cancers15071953

4. Rico M, Flamarique S, Casares C, et al. GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours. World J Clin Oncol. 2021;12(4):195-216. doi:10.5306/wjco.v12.i4.195

2035

Digital Poster

Salvage stereotactic radiosurgery after whole brain radiotherapy in non-small cell lung cancer

Filippa Sundbye 1 , Gitte Persson 1 , Søren Møller 2

1 Herlev Hospital, Oncology, Copenhagen, Denmark. 2 Rigshospitalet, Oncology, Copenhagen, Denmark

Purpose/Objective:

Patients with non-small cell lung cancer (NSCLC) are at high risk for developing brain metastases (BM). Stereotactic radiosurgery (SRS) is a well-established treatment for BM. However, the role of SRS as a salvage option after whole brain radiotherapy (WBRT) remains unclear. The purpose of this retrospective analysis is to examine the effect of salvage SRS after WBRT in a real-world cohort of patients with NSCLC.

Material/Methods:

All patients treated with SRS in the Capital Region of Denmark from 2012 to 2020 were registered in a database. Patients with NSCLC treated with salvage SRS after WBRT were identified from the database. Baseline characteristics, treatment information, and outcome data were retrieved. Time to intracranial progression and overall survival were analyzed using the Kaplan-Meier method.

SRS was linac-based using VMAT, RapidArc, Varian Medical Systems with a general dose of 18 Gy.

Results:

1432 patients were registered in the database. Of these, 33 were patients with NSCLC who received salvage SRS after WBRT. The median time between WBRT and salvage SRS was 17.1 months (range 4-106 months). Two (6 %) patients had ALK mutated and five (15 %) had EGFR mutated tumors. 1 BM in 26 (79%) patients and ≥ 2 BM (range 2 4) in 7 (21%) patients were treated with salvage SRS after WBRT. The median time to intracranial progression after salvage SRS was 3.0 months (95% CI 1.8-4.2), see figure 1. The pattern of recurrence was characterized by the following: In 5 (15%) of patients the recurrence was local, 5 (15%) had distant recurrence and for 4 (12%) recurrence was both local and distant. The median overall survival for this group of patients was 5.0 months (95% CI 2.2-7.8), see figure 2.